¿Cuál es el beneficio clínico de las nuevas opciones de tratamiento? ¿Qué dicen las guías?

Previous Page

Next Page

Page Background

PD-L1 como factor crucial en la selección de pacientes

para IO en monoterapia

•

Checkmate 026

1,2

–

60.4%

in the

chemotherapy

arm had

subsequent nivolumab

therapy—

crossover

allowed

–

32%

of patients in the

nivolumab

arm

and 47%

of patients in the

chemotherapy arm

had

≥50% PD-L1

expression

•

KEYNOTE-042

1,3

–

19.8%

in the

chemotherapy

arm had

subsequent

immunotherapy

(3% in

pembrolizumab arm)

–

47% of patients

in both

arms had

≥50% PD-L1

expression